Results 111 to 120 of about 130,251 (209)

EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy. [PDF]

JCI Insight
Ogino A, Vajdi A, Mu XJ, Mahadevan NR, Ngo K, Booker MA, Cejas P, Okoro JJ, Xu M, Springer BF, Eschle BK, Messier CM, Wang S, Syamala S, Tamen RM, Adeni AE, Chambers ES, Canadas I, Thai T, Christensen CL, Xu C, Lizotte PH, Oxnard GR, Watanabe H, Long HW, Gokhale PC, Paweletz CP, Sholl LM, Oser MG, Barbie DA, Tolstorukov MY, Jänne PA.   +31 more
europepmc   +1 more source

MEK Inhibitor SHR 7390 [PDF]

, 2020
openaire   +1 more source

Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma. [PDF]

JCI Insight
Pan S, Mirchia K, Payne E, Liu SJ, Al-Adli N, Peeran Z, Shukla P, Young JS, Gupta R, Wu J, Pak J, Ozawa T, Na B, Reddy AT, Braunstein SE, Phillips JJ, Chang S, Solomon DA, Perry A, Raleigh DR, Berger MS, Abate AR, Vasudevan HN.   +22 more
europepmc   +1 more source

MEK Inhibitor GDC-0623 [PDF]

, 2020
openaire   +1 more source

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma. [PDF]

Pigment Cell Melanoma Res
Tellenbach FL, Seiler L, Johnson M, Rehrauer H, Schukla P, Martinez-Gomez J, Stoffel CI, Kamal A, Dummer R, Levesque MP, Eichhoff OM.   +10 more
europepmc   +1 more source

BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer. [PDF]

Arch Endocrinol Metab
Finkel I, Korzets Y, Moore A, Coreanu T, Popovtzer A, Shoffel-Havakuk H, Bachar G, Mansour J, Weiss C, Robenshtok E.   +9 more
europepmc   +1 more source

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor. [PDF]

Front Pharmacol, 2023
Liu Y, Cheng Y, Huang G, Xia X, Wang X, Tian H.   +5 more
europepmc   +1 more source

Cutaneous Rosai-Dorfman disease with near-complete response to the MEK inhibitor cobimetinib. [PDF]

JAAD Case Rep
Rallapalle V, Kole L, Pavlidakey P, Bhambhvani P, Harada S, Ravindran A, Goyal G.   +6 more
europepmc   +1 more source

Fulminant Myocarditis Presenting With Refractory Ventricular Fibrillation During BRAF/MEK Inhibitor Therapy. [PDF]

JACC Case Rep
Lalario A, Rubbo FM, Bassetto G, Mazzaro E, Pinamonti M, Bussani R, Sinagra G, Stolfo D.   +7 more
europepmc   +1 more source

Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. [PDF]

Mol Cancer Ther
Mughees M, Tacam M, Tan AW, Pitner MK, Iles LR, Hu X, Villodre ES, Debeb BG, Kogawa T, Lim B, Layman RM, Woodward WA, Ueno NT, Tripathy D, Krishnamurthy S, Qi Y, Pusztai L, Wang J, Gandhi V, Bartholomeusz G, Bartholomeusz C.   +20 more
europepmc   +1 more source